Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsInfectious Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1398771

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1398771

Influenza Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 237 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global influenza diagnostics market is on the brink of significant expansion, with worldwide revenue reaching US$ 1.81 billion in 2024 and projected to reach a valuation of US$ 3.06 billion by the end of 2031. This growth is attributed to several key factors and innovations in diagnostic tests for influenza infection.

New Advancements in Diagnostic Tests for Influenza Infection Drive Growth

A range of diagnostic tools, including reverse transcription polymerase chain reaction (RT-PCR), viral cultures, fluorescence assays, serological tests, antigen testing, and rapid molecular assays, are available for influenza detection. Among these, commercial rapid flu diagnostic tests are the most widely used due to their ability to provide results with low to medium sensitivity and high specificity within just 15 minutes.

Molecular diagnostic assays represent a breakthrough in influenza testing, offering high sensitivity and specificity. Reverse transcription polymerase chain reaction (RT-PCR) and nucleic detection techniques have significantly improved the detection of respiratory viruses. Molecular tests utilize nucleic acid amplification testing (NAT) to identify specific known viruses, surpassing other diagnostic methods in various aspects.

Market Growth Impacted by Labor Shortage and High Testing Costs

Despite these advancements, the influenza diagnostics market faces challenges such as a shortage of skilled personnel and the high costs associated with molecular diagnostic procedures, reagents, and equipment. Developing nations, like India and China, often struggle to afford these expenses, limiting access to advanced diagnostic methods.

Additionally, rapid diagnostic approaches for influenza may have limitations in identifying specific viral subtypes, potentially leading to misinterpretations. To validate negative test results, expensive and time-consuming diagnostic tools are required, even in low influenza activity periods.

Country-wise Insights

U.S. Market Boom Driven by Increasing Prevalence

The United States, experiencing a rising prevalence of influenza, is expected to witness a surge in the adoption of diagnostic kits. Influenza is the most commonly diagnosed condition in the U.S., with a substantial number of cases reported. Key industrial firms like Abbott and Quidel Corporation contribute to market expansion through the development and marketing of new products.

Germany - A Lucrative Market for Innovative Kits

Germany is poised to dominate the regional market for rapid influenza diagnostic tests due to increasing influenza prevalence, supportive government interventions, influential industry leaders, and advanced facilities. The presence of manufacturing facilities and collaborative research efforts further enhance access to influenza testing kits.

Japan's Prominence in Influenza Diagnostics

Japan emerges as a prominent market for rapid influenza diagnostics, driven by a modern healthcare system, favorable legislation, and insurance. The country's expanding market is also associated with research advancements in influenza diagnostics technology, a growing geriatric population, and the demand for rapid disease diagnostics.

Competitive Landscape

Mergers and acquisitions are key growth strategies in the global influenza diagnostics market. Leading organizations are expanding their product lines through strategic partnerships and acquisitions. Key players in the market include:

  • Abbott Laboratories
  • Endress+Hauser (Analytik Jena AG)
  • Becton, Dickinson and Company
  • Biocartis
  • bioMerieux Inc
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic

Key Segments Covered in Influenza Diagnostics Industry Research

Test:

  • Molecular Diagnostic Test
    • RT-PCR
    • LAMP
    • NASABA
  • Traditional Diagnostic Test
    • Rapid Influenza Detection Test
    • Serological Assays
    • Direct Fluorescent Antibody
    • Viral Culture
    • H1N1 Influenza A Virus Identification Kits
    • Immunoassay Kits
    • Immunofluorescence Antibody Assay

Type of Flu:

  • Type A Flu
  • Type B Flu
  • Type C Flu

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Institute
  • Contract Research Organization (CRO's)

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Influenza Diagnostics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Influenza Diagnostics Market Outlook, 2018 - 2031

  • 3.1. Global Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Molecular Diagnostic Test
        • 3.1.1.1.1. RT-PCR
        • 3.1.1.1.2. LAMP
        • 3.1.1.1.3. NASABA
      • 3.1.1.2. Traditional Diagnostic Test
        • 3.1.1.2.1. Rapid Influenza Detection Test
        • 3.1.1.2.2. Serological Assays
        • 3.1.1.2.3. Direct Fluorescent Antibody
        • 3.1.1.2.4. Viral Culture
        • 3.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 3.1.1.2.6. Immunoassay Kits
        • 3.1.1.2.7. Immunofluorescence Antibody Assay
  • 3.2. Global Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Type A Flu
      • 3.2.1.2. Type B Flu
      • 3.2.1.3. Type C Flu
  • 3.3. Global Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Diagnostic Laboratories
      • 3.3.1.3. Research & Academic Institute
      • 3.3.1.4. Contract Research Organization (CRO's)
  • 3.4. Global Influenza Diagnostics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Influenza Diagnostics Market Outlook, 2018 - 2031

  • 4.1. North America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Molecular Diagnostic Test
        • 4.1.1.1.1. RT-PCR
        • 4.1.1.1.2. LAMP
        • 4.1.1.1.3. NASABA
      • 4.1.1.2. Traditional Diagnostic Test
        • 4.1.1.2.1. Rapid Influenza Detection Test
        • 4.1.1.2.2. Serological Assays
        • 4.1.1.2.3. Direct Fluorescent Antibody
        • 4.1.1.2.4. Viral Culture
        • 4.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 4.1.1.2.6. Immunoassay Kits
        • 4.1.1.2.7. Immunofluorescence Antibody Assay
  • 4.2. North America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Type A Flu
      • 4.2.1.2. Type B Flu
      • 4.2.1.3. Type C Flu
  • 4.3. North America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Diagnostic Laboratories
      • 4.3.1.3. Research & Academic Institute
      • 4.3.1.4. Contract Research Organization (CRO's)
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Influenza Diagnostics Market Outlook, 2018 - 2031

  • 5.1. Europe Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Molecular Diagnostic Test
        • 5.1.1.1.1. RT-PCR
        • 5.1.1.1.2. LAMP
        • 5.1.1.1.3. NASABA
      • 5.1.1.2. Traditional Diagnostic Test
        • 5.1.1.2.1. Rapid Influenza Detection Test
        • 5.1.1.2.2. Serological Assays
        • 5.1.1.2.3. Direct Fluorescent Antibody
        • 5.1.1.2.4. Viral Culture
        • 5.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 5.1.1.2.6. Immunoassay Kits
        • 5.1.1.2.7. Immunofluorescence Antibody Assay
  • 5.2. Europe Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Type A Flu
      • 5.2.1.2. Type B Flu
      • 5.2.1.3. Type C Flu
  • 5.3. Europe Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Diagnostic Laboratories
      • 5.3.1.3. Research & Academic Institute
      • 5.3.1.4. Contract Research Organization (CRO's)
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Influenza Diagnostics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Molecular Diagnostic Test
        • 6.1.1.1.1. RT-PCR
        • 6.1.1.1.2. LAMP
        • 6.1.1.1.3. NASABA
      • 6.1.1.2. Traditional Diagnostic Test
        • 6.1.1.2.1. Rapid Influenza Detection Test
        • 6.1.1.2.2. Serological Assays
        • 6.1.1.2.3. Direct Fluorescent Antibody
        • 6.1.1.2.4. Viral Culture
        • 6.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 6.1.1.2.6. Immunoassay Kits
        • 6.1.1.2.7. Immunofluorescence Antibody Assay
  • 6.2. Asia Pacific Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Type A Flu
      • 6.2.1.2. Type B Flu
      • 6.2.1.3. Type C Flu
  • 6.3. Asia Pacific Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Diagnostic Laboratories
      • 6.3.1.3. Research & Academic Institute
      • 6.3.1.4. Contract Research Organization (CRO's)
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Influenza Diagnostics Market Outlook, 2018 - 2031

  • 7.1. Latin America Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Molecular Diagnostic Test
        • 7.1.1.1.1. RT-PCR
        • 7.1.1.1.2. LAMP
        • 7.1.1.1.3. NASABA
      • 7.1.1.2. Traditional Diagnostic Test
        • 7.1.1.2.1. Rapid Influenza Detection Test
        • 7.1.1.2.2. Serological Assays
        • 7.1.1.2.3. Direct Fluorescent Antibody
        • 7.1.1.2.4. Viral Culture
        • 7.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 7.1.1.2.6. Immunoassay Kits
        • 7.1.1.2.7. Immunofluorescence Antibody Assay
  • 7.2. Latin America Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Type A Flu
      • 7.2.1.2. Type B Flu
      • 7.2.1.3. Type C Flu
  • 7.3. Latin America Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Diagnostic Laboratories
      • 7.3.1.3. Research & Academic Institute
      • 7.3.1.4. Contract Research Organization (CRO's)
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Influenza Diagnostics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Influenza Diagnostics Market Outlook, by Test, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Molecular Diagnostic Test
        • 8.1.1.1.1. RT-PCR
        • 8.1.1.1.2. LAMP
        • 8.1.1.1.3. NASABA
      • 8.1.1.2. Traditional Diagnostic Test
        • 8.1.1.2.1. Rapid Influenza Detection Test
        • 8.1.1.2.2. Serological Assays
        • 8.1.1.2.3. Direct Fluorescent Antibody
        • 8.1.1.2.4. Viral Culture
        • 8.1.1.2.5. H1N1 Influenza A Virus Identification Kits
        • 8.1.1.2.6. Immunoassay Kits
        • 8.1.1.2.7. Immunofluorescence Antibody Assay
  • 8.2. Middle East & Africa Influenza Diagnostics Market Outlook, by Type of Flu, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Type A Flu
      • 8.2.1.2. Type B Flu
      • 8.2.1.3. Type C Flu
  • 8.3. Middle East & Africa Influenza Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Diagnostic Laboratories
      • 8.3.1.3. Research & Academic Institute
      • 8.3.1.4. Contract Research Organization (CRO's)
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Influenza Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Influenza Diagnostics Market by Test, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Influenza Diagnostics Market by Type of Flu, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Influenza Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Segment 3 vs by Type of Flu Heat map
  • 9.2. Manufacturer vs by Type of Flu Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Abbott Laboratories
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Endress+Hauser (Analytik Jena AG)
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Becton, Dickinson and Company
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Biocartis
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. bioMerieux Inc
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Danaher Corporation (Cepheid)
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. F. Hoffmann-La Roche Ltd
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. GenMark Diagnostics, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Luminex Corporation
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Quidel Corporation
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Genesis Biosystems, Inc.
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Thermo Fisher Scientific Inc.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Hologic
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!